GLP-1 receptor agonists, body composition, skeletal muscle and risk of  sarcopaenia: from promising findings in animal models to debated concern in human studies.

Scheen, André

doi:10.1016/j.diabet.2025.101681

Article (Scientific journals)

GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.

Scheen, André

2025 • In Diabetes and Metabolism, 51 (5), p. 101681

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/340968

DOI
10.1016/j.diabet.2025.101681

PubMed
40571191

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

TXT Clean revised version AS Sarcopenia.docx

Author postprint (65.67 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Glucagon-Like Peptide-1 Receptor Agonists; Hypoglycemic Agents; Humans; Body Composition/drug effects; Animals; Muscle, Skeletal/drug effects; Sarcopenia/chemically induced; Diabetes Mellitus, Type 2/drug therapy/complications; Obesity/drug therapy; Hypoglycemic Agents/therapeutic use/adverse effects; Disease Models, Animal; Body composition – GLP-1 receptor agonist – Muscle – Obesity – Sarcopenia – Weight loss; Replace Sarcopenia by Sarcopaenia

Abstract :

[en] BACKGROUND: - Glucagon-like peptide-1 (GLP-1)-based therapies induce a clinically relevant weight loss, which is associated with overall better prognosis in people with type 2 diabetes and/or clinical obesity. However, a risk of excessive reduction in fat-free mass (FFM) and skeletal muscle mass (SSM), potentially leading to sarcopaenia in at-risk patients, is currently a matter of debate as this negative effect could minimize their benefit/risk balance. METHODS: - An extensive literature search to detect animal and human studies that investigated the effects of GLP-1-based therapies on changes in body composition (FFM and SMM), muscle strength, structure, and function. RESULTS: - Favourable effects on SMM, intramuscular lipid deposition, inflammation and mitochondrial health were consistently reported in different rodent models with GLP-based therapies. However, mixed results were reported in human studies, some reported an excessive FFM/SMM loss while others arguing for a protective effect against sarcopaenia (including less myosteatosis). This controversy may result from misinterpretation of SMM derived from FFM changes and a lack of studies that properly investigate SMM, muscle function and structure in humans. CONCLUSION: - Maximizing fat loss while preserving lean (muscle) tissue mass and function is a central goal of modern obesity pharmacological treatments. Currently, available data preclude to have a definite conclusion about positive/negative effects of GLP-1-based therapies on muscle. Further investigations using accurate methodologies to assess not only SMM but also muscle structure, function (strength) and performance are needed to better analyse the effects of GLP-1-based therapies, especially among individuals at higher risk of sarcopaenia, older patients and frail people.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques

Language :

English

Title :

GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.

Publication date :

September 2025

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Elsevier Masson, Paris, Fr

Volume :

Issue :

Pages :

101681

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 03 February 2026

Statistics

Number of views

5 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Rubino, F., Cummings, D.E., Eckel, R.H., Cohen, R.V., Wilding, J.P.H., Brown, W.A., et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 13 (2025), 221–262.
Busetto, L., Dicker, D., Fruhbeck, G., Halford, J.C.G., Sbraccia, P., Yumuk, V., et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30 (2024), 2395–2399.
McCarthy, D., Berg, A., Weight loss strategies and the risk of skeletal muscle mass loss. Nutrients, 13, 2021, 2473.
Cava, E., Yeat, N.C., Mittendorfer, B., Preserving healthy muscle during weight loss. Adv Nutr 8 (2017), 511–519.
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S.K., Kokkinos, A., The effect of obesity pharmacotherapy on body composition, including muscle mass. Int J Obes 49 (2025), 381–387.
Prado, C.M., Phillips, S.M., Gonzalez, M.C., Heymsfield, S.B., Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol 12 (2024), 785–787.
Sedlmeier, A.M., Baumeister, S.E., Weber, A., Fischer, B., Thorand, B., Ittermann, T., et al. Relation of body fat mass and fat-free mass to total mortality: results from 7 prospective cohort studies. Am J Clin Nutr 113 (2021), 639–646.
Bloomgarden, Z., Sarcopenia. J Diabetes, 16, 2024, e70025.
Kirk, B., Cawthon, P.M., Arai, H., Avila-Funes, J.A., Barazzoni, R., Bhasin, S., et al. The conceptual definition of sarcopenia: delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing, 53, 2024, afae052.
Cesari, M., Bernabei, R., Vellas, B., Fielding, R.A., Rooks, D., Azzolino, D., et al. Challenges in the development of drugs for sarcopenia and frailty - report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force. J Frailty Aging 11 (2022), 135–142.
Donini, L.M., Busetto, L., Bischoff, S.C., Cederholm, T., Ballesteros-Pomar, M.D., Batsis, J.A., et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 15 (2022), 321–335.
Wannamethee, S.G., Atkins, J.L., Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 74 (2015), 405–412.
Prado, C.M., Batsis, J.A., Donini, L.M., Gonzalez, M.C., Siervo, M., Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol 20 (2024), 261–277.
Caturano, A., Amaro, A., Berra, C.C., Conte, C., Sarcopenic obesity and weight loss-induced muscle mass loss. Curr Opin Clin Nutr Metab Care 28 (2025), 339–350.
Massimino, E., Izzo, A., Riccardi, G., Della Pepa, G., The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells, 10, 2021, 1958.
Lisco, G., Disoteo, O.E., De Tullio, A., de Geronimo, V., Giagulli, V.A., Monzani, F., et al. Sarcopenia and diabetes: a detrimental liaison of advancing age. Nutrients, 16, 2023, 63.
Henson, J., Baker, L.A., Watson, E., Yates, T., Davies, M.J., Type 2 diabetes and accelerated ageing in skeletal muscle. Lancet Diabetes Endocrinol 13 (2025), 362–364.
Anyiam, O., Ardavani, A., Rashid, R.S.A., Panesar, A., Idris, I., How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. Obes Rev, 26, 2025, e13916.
Ida, S., Kaneko, R., Imataka, K., Okubo, K., Shirakura, Y., Azuma, K., et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev 17 (2021), 293–303.
Zhang, X., Zhao, Y., Chen, S., shao, H., Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Mus 12 (2021), 1368–1379.
Ma, X.Y., Chen, F.Q., Effects of anti-diabetic drugs on sarcopenia: best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J Clin Cases 9 (2021), 10064–10074.
Witham, M.D., Granic, A., Pearson, E., Robinson, S.M., Sayer, A.A., Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - a narrative review. Drugs Aging 40 (2023), 703–719.
Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65 (2022), 1925–1966.
American Diabetes Association Professional Practice C. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care 48 (2025), S181–S206 Supplement–1.
Drucker, D.J., GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov, 2025; Apr 25, 10.1038/s41573-025-01183-8.
Moll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine, 73, 2024, 102661.
Linge, J., Birkenfeld, A.L., Neeland, I.J., Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or aladaptive response to weight loss?. Circulation 150 (2024), 1288–1298.
Tufail, E., Sanyal, S., Mithal, A., Sanyal, S., Chattopadhyay, N., The role of glucagon-like peptides in osteosarcopenia. J Endocrinol, 264, 2025, e240210.
Conte, C., Hall, K.D., Klein, S., Is weight loss-induced muscle mass loss clinically relevant?. JAMA 332 (2024), 9–10.
Heymsfield, S.B., Brown, J., Ramirez, S., Prado, C.M., Tinsley, G.M., Gonzalez, M.C., Are lean body mass and fat-free mass the same or different body components? a critical perspective. Adv Nutr, 15, 2024, 100335.
Carter, J., Husain, F., Papasavas, P., Docimo, S., Albaugh, V., Aylward, L., et al. American society for metabolic and bariatric surgery review of body composition. Surg Obes Relat Dis 21 (2025), 354–361.
Rodriguez, C., Mota, J.D., Palmer, T.B., Heymsfield, S.B., Tinsley, G.M., Skeletal muscle estimation: a review of techniques and their applications. Clin Physiol Funct Imaging 44 (2024), 261–284.
Heymsfield, S.B., Gonzalez, M.C., Shen, W., Redman, L., Thomas, D., Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 15 (2014), 310–321.
Ashtary-Larky, D., Ghanavati, M., Lamuchi-Deli, N., Payami, S.A., Alavi-Rad, S., Boustaninejad, M., et al. Rapid weight loss vs. slow weight loss: which is more effective on body composition and metabolic risk factors?. Int J Endocrinol Metab, 15, 2017, e13249.
Chaston, T.B., Dixon, J.B., O'Brien, P.E, Changes in fat-free mass during significant weight loss: a systematic review. Int J Obes 31 (2007), 743–750.
Tinsley, G.M., Heymsfield, S.B., Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. J Endocr Soc, 8, 2024, bvae164.
Faria, I., Samreen, S., McTaggart, L., Arentson-Lantz, E.J., Murton, A.J., The etiology of reduced muscle mass with surgical and pharmacological weight loss and the identification of potential countermeasures. Nutrients, 17, 2024, 132.
Grosicki, G.J., Dhurandhar, N.V., Unick, J.L., Arent, S.M., Thomas, J.G., Lofton, H., et al. Sculpting success: the importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications. Curr Dev Nutr, 8, 2024, 104486.
Jassil, F.C., Papageorgiou, M., Mackay, E., Carnemolla, A., Kigett, H., Doyle, J., et al. One year changes in body composition and musculoskeletal health following metabolic/bariatric surgery. J Clin Endocrinol Metab, 110, 2025 e1598–e608.
Ibacache-Saavedra, P., Martinez-Rosales, E., Jerez-Mayorga, D., Miranda-Fuentes, C., Artero, E.G., Cano-Cappellacci, et al. Effects of bariatric surgery on muscle strength and quality: a systematic review and meta-analysis. Obes Rev, 25, 2024, e13790.
Karakasis, P., Patoulias, D., Fragakis, N., Mantzoros, C.S., Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism, 164, 2025, 156113.
Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y., Lv, F., et al. Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis. Diabetes Obes Metab 27 (2025), 259–267.
Rochira, V., Greco, C., Boni, S., Costantino, F., Dalla Valentina, L., Zanni, E., et al. The effect of tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies. Diseases, 12, 2024, 204.
Look, M., Dunn, J.P., Kushner, R.F., Cao, D., Harris, C., Gibble, T.H., et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 27 (2025), 2720–2729.
Sargeant, J.A., Henson, J., King, J.A., Yates, T., Khunti, K., Davies, M.J., A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab 34 (2019), 247–262.
Neeland, I.J., Linge, J., Birkenfeld, A.L., Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 26:Suppl 4 (2024), 16–27.
Dubin, R.L., Heymsfield, S.B., Ravussin, E., Greenway, F.L., Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: filling the gaps. Diabetes Obes Metab 26 (2024), 5503–5518.
Locatelli, J.C., Costa, J.G., Haynes, A., Naylor, L.H., Fegan, P.G., Yeap, B.B., et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?. Diabetes Care 47 (2024), 1718–1730.
Li, Z., Ni, C.L., Yao, Z., Chen, M.L., Niu, W.Y., Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells. Metabolism 63 (2014), 1022–1030.
Xu, F., Cao, H., Chen, Z., Gu, H., Guo, W., Lin, B., et al. Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice. Int J Obes 44 (2020), 937–947.
Szekeres, Z., Nagy, A., Jahner, K., Szabados, E., Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review. Int J Mol Sci, 25, 2024, 8214.
Colin, I.M., Knoops, B., Gerard, A.C., Incretin-induced changes in the transcriptome of skeletal muscles of fa/fa Zucker rat (ZFR) with obesity, without diabetes. Int J Obes 46 (2022), 1311–1318.
Chan, D.C., Lin, Y.C., Tzeng, H.P., Yang, R.S., Chiang, M.T., Liu, S.H., Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin. Tissue Cell, 89, 2024, 102479.
Hong, Y., Lee, J.H., Jeong, K.W., Choi, C.S., Jun, H.S., Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Mus 10 (2019), 903–918.
Xiang, J., Qin, L., Zhong, J., Xia, N., Liang, Y., GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes 16 (2023), 2433–2446.
Mukai, R., Kojima, A., Morisasa, M., Tawara, W., Mori, T., Goto-Inoue, N., Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells. Biosci Biotechnol Biochem, 2025; Apr 21, zbaf060.
Fan, D., Wang, Y., Liu, B., Yin, F., Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy. J Chin Med Assoc 86 (2023), 166–175.
Yamada, S., Ogura, Y., Inoue, K., Tanabe, J., Sugaya, T., Ohata, K., et al. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol, 539, 2022, 111472.
Gurjar, A.A., Kushwaha, S., Chattopadhyay, S., Das, N., Pal, S., Pal China, S., et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism, 103, 2020, 154044.
Xu, Q., Qiu, X., Di, H., Li, Z., Liu, Z., Liu, K., Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway. J Diabetes Complic, 39, 2025, 108975.
Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., et al. An effective glucagon-like peptide-1 receptor agonists, semaglutide, improves sarcopenic obesity in obese mice by modulating skeletal muscle metabolism. Drug Des Devel Ther 16 (2022), 3723–3735.
Iwai, S., Kaji, K., Nishimura, N., Kubo, T., Tomooka, F., Shibamoto, A., et al. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochim Biophys Acta Mol Basis Dis, 1869, 2023, 166770.
Choi, R.H., Karasawa, T., Meza, C.A., Maschek, J.A., Manuel, A.M., Nikolova, L.S., et al. Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle. Obesity 33 (2025), 974–985.
Deng, F., Wu, W., Fan, X., zhong, X., Wang, N., Wang, Y., et al. Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. Int J Endocrinol, 2023, 2023, 9926462.
Khin, P.P., Hong, Y., Yeon, M., Lee, D.H., Lee, J.H., Jun, H.S., Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice. Aging 13 (2021), 21962–21974.
Nguyen, T.T.N., Choi, H., Jun, H.S., Preventive effects of dulaglutide on disuse muscle atrophy through inhibition of inflammation and apoptosis by induction of Hsp72 expression. Front Pharmacol, 11, 2020, 90.
Huang, H.H., Wang, Y.J., Jiang, H.Y., Yu, H.W., Chen, Y.Q., Chiou, A., et al. Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation. J Cachexia Sarcopenia Mus 15 (2024), 1708–1721.
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab, 80, 2024, 101880.
Old, V.J., Davies, M.J., Papamargaritis, D., Choudhary, P., Watson, E.L., The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review. J Cachexia Sarcopenia Mus, 16, 2025, e13677.
Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol, 14, 2023, 1148209.
Alharbi, S.H., Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab, 15, 2024, 20420188231222367.
Rajagopal, S., Alruwaili, F., Mavratsas, V., Serna, M.K., Murthy, V.L., Raji, M., Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications. Cureus, 15, 2023, e51352.
Schmidt, P.H.S., Pasqualotto, E., Dos Santos, H.V., de Souza, L.S.N., Dos Santos, B.E., Chavez, M.P, et al. Effects of liraglutide on body composition in people living with obesity or overweight: a systematic review. Obes Res Clin Pract 19 (2025), 11–18.
Grannell, A., Martin, W.P., Dehestani, B., Al-Najim, W., Murphy, J.C., le Roux, C.W., Liraglutide does not adversely impact fat-free mass loss. Obesity 29 (2021), 529–534.
Ishii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series. J Clin Med Res 11 (2019), 219–224.
Perna, S., Guido, D., Bologna, C., Solerte, S.B., Guerriero, F., Isu, A., et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. a perspective case series study. Aging Clin Exp Res 28 (2016), 1251–1257.
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T.K., Kontogiorgis, C., A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother 25 (2024), 611–619.
Rodriguez Jimenez, B., Rodriguez de Vera Gomez, P., Belmonte Lomas, S., Mesa Diaz, A., Mateos, I.C., Galan, I., et al. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front Endocrinol, 15, 2024, 1386542.
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., et al. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Front Endocrinol, 14, 2023, 1240263.
Uchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., Tanaka, Y., Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes. J Clin Med Res 15 (2023), 377–383.
Xiang, J., Ding, X.Y., Zhang, W., Zhang, J., Zhang, Y.S., Li, Z.M., et al. Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults. Eur Rev Med Pharmacol Sci 27 (2023), 9908–9915.
Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study. Medicines, 9, 2022, 47.
Ditzenberger, G.L., Lake, J.E., Kitch, D.W., Kantor, A., Muthupillai, R., Moser, C., et al. Effects of semaglutide on muscle structure and function in the SLIM LIVER study. Clin Infect Dis 80 (2025), 389–396.
Zinn, J., Poretsky, L., Skeletal muscle mass and body weight fall proportionally with use of dual glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide: case report and review of literature. AACE Clin Case Rep 11 (2025), 98–101.
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., Cobellis, L., et al. Preliminary evidence suggests that a 12-week treatment with tirzepatide plus low-energy ketogenic therapy is more effective than its combination with a low-calorie diet in preserving fat-free mass, muscle strength, and resting metabolic rate in patients with obesity. Nutrients, 17, 2025, 1216.
Gudzune, K.A., Stefanski, A., Cao, D., Mojdami, D., Wang, F., Ahmad, N., et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diabetes Obes Metab 27 (2025), 539–550.
Rahemi, H., Nigam, N., Wakeling, J.M., The effect of intramuscular fat on skeletal muscle mechanics: implications for the elderly and obese. J R Soc Interface, 12, 2015, 20150365.
Pandey, A., Patel, K.V., Segar, M.W., Ayers, C., Linge, J., Leinhard, O.D., et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. J Cachexia Sarcopenia Mus 15 (2024), 1072–1083.
Kakegawa, T., Sugimoto, K., Saito, K., Yunaiyama, D., Araki, Y., Wada, T., et al. Favorable liver and skeletal muscle changes in patients with MASLD and T2D receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study. Medicine, 103, 2024, e38444.
Nelson, L.W., Lee, M.H., Garrett, J.W., Pickhardt, S.G., Warner, J.D., Summers, R.M., et al. Intrapatient changes in CT-based body composition after initiation of semaglutide (glucagon-like peptide-1 receptor agonist) therapy. AJR Am J Roentgenol, 223, 2024, e2431805.
Mechanick, J.I., Butsch, W.S., Christensen, S.M., Hamdy, O., Li, Z., Prado, C.M., et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev, 26, 2025, e13841.
Ikejima, S., Kondo, S., Sakai, T., Taniai, H., Takahashi, T., Umezi, J., et al. Novel approach to sarcopenia in diabetic patients treated with GLP-1 receptor agonists (GLP-1RA) (abstract). Diabetes, 67, 2018, 673.
Papakonstantinou, I., Tsioufis, K., Katsi, V., Spotlight on the mechanism of action of semaglutide. Curr Issues Mol Biol 46 (2024), 14514–14541.
Ellis, K.J., Human body composition: in vivo methods. Physiol Rev 80 (2000), 649–680.
Tosato, M., Marzetti, E., Cesari, M., Savera, G., Miller, R.R., Bernabei, R., et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res 29 (2017), 19–27.
Sizoo, D., de Heide, L.J.M., Emous, M., van Zutphen, T., Navis, G., van Beek, A.P., Measuring muscle mass and strength in obesity: a review of various methods. Obes Surg 31 (2021), 384–393.
Heymsfield, S.B., Gonzalez, M.C., Lu, J., Jia, G., Zheng, J., Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc 74 (2015), 355–366.
Wang, D., Zhang, G., Yu, Y., Zhang, Z., Imaging of sarcopenia in type 2 diabetes mellitus. Clin Interv Aging 19 (2024), 141–151.
Buckinx, F., Landi, F., Cesari, M., Fielding, R.A., Visser, M., Engelke, K., et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Mus 9 (2018), 269–278.
Jensen, B., Braun, W., Geisler, C., Both, M., Klückmann, K., Müller, M.J., et al. Limitations of fat-free mass for the assessment of muscle mass in obesity. Obes Facts 12 (2019), 307–315.
Bosy-Westphal, A., Kossel, E., Goele, K., Later, W., Hitze, B., Settler, U., et al. Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure. Am J Clin Nutr 90 (2009), 993–1001.
Tavoian, D., Ampomah, K., Amano, S., Law, T.D., Clark, B.C., Changes in DXA-derived lean mass and MRI-derived cross-sectional area of the thigh are modestly associated. Sci Rep, 9, 2019, 10028.
Faron, A., Sprinkart, A.M., Kuetting, D.L.R., Feisst, A., Isaak, A., Endler, C., et al. Body composition analysis using CT and MRI: intra-individual intermodal comparison of muscle mass and myosteatosis. Sci Rep, 10, 2020, 11765.
Sattar, N., Neeland, I.J., Dahlqvist Leinhard, O., Lando, L.F., Bray, R., Linge, J., et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 13 (2025), 482–493.
Ashtary-Larky, D., Bagheri, R., Abbasnezhad, A., Tinsley, G.M., Alipour, M., Wong, A., Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis. Br J Nutr 124 (2020), 1121–1132.
Nuijten, M.A.H., Eijsvogels, T.M.H., Monpellier, V.M., Jannssen, I.M.C., Hazebroek, E.J., Hopman, M.T.E., The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis. Obes Rev, 23, 2022, e13370.
Kong, J., Park, S., Kim, T.H., Lee, J.E., Cho, H., Oh, J., et al. Worldwide burden of antidiabetic drug-induced sarcopenia: an international pharmacovigilance study. Arch Gerontol Geriatr, 129, 2025, 105656.
Liang, Y., Luo, S., Wan, E.Y.F., Cheung, C.L., Gill, D., Yeung, S.L.A., Relative effects of genetically proxied glucagon-like peptide-1 receptor agonism on muscle and fat mass: a mendelian randomization study. Diabetes Obes Metab 27 (2025), 2280–2283.
Koo, B.K., Assessment of muscle quantity, quality and function. J Obes Metab Syndr 31 (2022), 9–16.
Riviati, N., Indra, B., Relationship between muscle mass and muscle strength with physical performance in older adults: a systematic review. SAGE Open Med, 11, 2023, 20503121231214650.
Zibellini, J., Seimon, R.V., Lee, C.M., Gibson, A.A., Hsu, M.S.H., Sainbury, A., Effect of diet-induced weight loss on muscle strength in adults with overweight or obesity - a systematic review and meta-analysis of clinical trials. Obes Rev 17 (2016), 647–663.
Czernichow, S., Rassy, N., Carette, C., Shoung, N., Hu, F.B., Rives-Lange C. Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-a systematic mapping review. Obes Rev, 26, 2025, e13890.
Correa-de-Araujo, R., Addison, O., Miljkovic, I., Goodpaster, B.H., Bergman, B.C., Clark, R.V., et al. Myosteatosis in the context of skeletal muscle function deficit: an interdisciplinary workshop at the National Institute on. Aging Front Physiol, 11, 2020, 963.
Linge, J., Nasr, P., Sanyal, A.J., Leinhard, O.D., Ekstedt, M., Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP Rep, 5, 2023, 100663.
Visser, M., Goodpaster, B.H., Kritchevsky, S.B., et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 60:3 (2005), 324–333.
Pantanetti, P., Cangelosi, G., Alberti, S., Di Marco, S., Michetti, G., Cerasoli, G., et al. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front Endocrinol, 15, 2024, 1394506.
Chao, C.T., Kovesdy, C.P., Merchant, R.A., Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review. Kidney Res Clin Pract, 2025; Jan 21, 10.23876/j.krcp.24.207.
Deng, C., Ou, Q., Ou, X., Pan, D., Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis. BMJ Open, 14, 2024, e078933.
Damluji, A.A., Alfaraidhy, M., AlHajri, N., rohant, N.N., Kumar, M., Al Malouf, C., et al. Sarcopenia and cardiovascular diseases. Circulation 147 (2023), 1534–1553.
Memel, Z., Gold, S.L., Pearlman, M., Muratore, A., Martindale, R., Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep, 14, 2025, 63.
Badve, S.V., Bilal, A., Lee, M.M.Y., Sattar, N., Gerstein, H.C., Rull, C.T., et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 13 (2025), 15–28.
Driggin, E., Goyal, P., Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF. J Card Fail 30 (2024), 610–612.
Hong, S.H., Bae, Y.J., Association between alcohol consumption and the risk of sarcopenia: a systematic review and meta-analysis. Nutrients, 14, 2022, 3266.
Skinner, J., Shepstone, L., Hickson, M., Welch, A.A., Alcohol consumption and measures of sarcopenic muscle risk: cross-sectional and prospective associations within the UK Biobank study. Calcif Tissue Int 113 (2023), 143–156.
Scheen, A.J., Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists. Diabetes Metab, 51, 2025, 101612.
Scheen, A.J., Glucagon-like peptide-1 receptor agonists and alcohol use disorders: an emerging unexpected beneficial effect. Diabetes Obes Metab, 2025; May 13, 10.1111/dom.16453.
Malin, S.K., Understanding the benefit of combining GLP-1 agonists with exercise: time will tell. J Clin Endocrinol Metab 109 (2024), e860–ee61.
Ryan, D.H., New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?. Rev Endocr Metab Disord, 2025; May 5, 10.1007/s11154-025-09967-4.
Stefanakis, K., Kokkorakis, M., Mantzoros, C.S., The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism, 161, 2024, 156057.